| Literature DB >> 21327864 |
Yaohua Liu1, Yuan Liang, Tianhu Zheng, Guang Yang, Xu Zhang, Zhe Sun, Changbin Shi, Shiguang Zhao.
Abstract
We have previously reported that arsenic trioxide (ATO) could inhibit glioma growth both in vitro and in vivo, and demonstrated its potent therapeutic effects on gliomas. In this study we showed that ATO induced cell damage and heme oxygenase-1 (HO-1) expression in glioma cells via ROS generation. HO-1 inducer clearly protected from ATO-induced cell death and ROS generation, and HO-1 inhibitor led to a significant increase in cell death and ROS generation induced by ATO. In addition, knockdown of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) strongly inhibited HO-1 expression induced by ATO, and significantly enhanced ATO-induced oxidative damage. Our results demonstrated, for the first time, that HO-1 inhibition or Nrf2 knockdown significantly potentiated ATO's effects on glioma cells. Considering that HO-1 is highly expressed in glioma tissues, administration of ATO in combination with either HO-1 inhibitor or Nrf2 knockdown may act as a new approach to the treatment of glioma.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21327864 DOI： 10.1007/s11060-010-0513-1
Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130